Please assess the completion status of the following clinical trial:

Trial Title: Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pre-PRP protocol refraction, fluorescein angiography, and optical coherence tomography AND 7-14 day post-PRP OCT~* Ability to provide written informed consent and comply with study assessments for the full duration of the study~* Age 21 years or older~* Previously untreated PDR patients with high risk characteristics who develop edema within 7-14 days post PRP therapy. This edema, determined by a masked investigator, will be characterized as either increased foveal thickness (\>10% increase from pre-PRP foveal thickness), and/or increased macular volume on OCT (\>10% increase from pre-PRP macular volume).~Exclusion Criteria:~* Pregnancy (positive pregnancy test) prior to enrollment in the study~* Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated.~* Participation in another simultaneous medical investigation or trial~* Pre-PRP clinically significant diabetic macular edema (CSME) that would make the patient eligible for macular laser prior to PRP~* Neovascularization of the iris or neovascular glaucoma~* Increased central foveal thickness for any other reason~* Concurrent macular diseases that could confound the results of this study~* Prior vitrectomy in the study eye~* Prior treatment with intravitreal injection including pegaptanib sodium, ranibizumab, bevacizumab or triamcinolone acetonide

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab (Type: EXPERIMENTAL): Ranibizumab is being used off-label to test the safety and efficacy of its use in Diabetic Macular Edema post panretinal photocoagulation. Ranibizumab 0.5mg at baseline and then again at 30 days and/or 60 days after PRP as deemed appropriate by the Investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).